Free for academic non-profit institutions. Other users need a Commercial license
This gene encodes a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, this kinase translocates to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. One study also suggests that this protein acts as a transcriptional repressor independent of its kinase activity. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Two alternatively spliced transcript variants encoding the same protein, but differing in the UTRs, have been reported for this gene. [provided by RefSeq, Jan 2014]
MAPK1 (Mitogen-Activated Protein Kinase 1) is a Protein Coding gene. Diseases associated with MAPK1 include Chromosome 22Q11.2 Deletion Syndrome, Distal and Pertussis. Among its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is MAPK3.
Extracellular signal-regulated kinases are a group of mitogen-activated protein kinases (MAPK) that mediate intracellular signaling. ERK1 and ERK2 (MAPK3 and MAPK1) transduce signals from growth factors and phorbol esters. They are expressed in all tissues, at varying levels.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000166 | nucleotide binding | IEA | -- |
GO:0001784 | phosphotyrosine residue binding | IEA | -- |
GO:0003677 | DNA binding | IEA | -- |
GO:0003690 | double-stranded DNA binding | IEA | -- |
GO:0004672 | protein kinase activity | IEA | -- |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005576 | extracellular region | TAS | -- |
GO:0005623 | cell | IEA | -- |
GO:0005634 | nucleus | IBA,TAS | 19565474 |
GO:0005654 | nucleoplasm | TAS | -- |
GO:0005737 | cytoplasm | IBA,ISS | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | RET signaling |
.92
|
.92
|
2 | Activated TLR4 signalling | ||
3 | IL-2 Pathway |
ErbB Family Pathway
.59
ErbB4 Pathway
.59
Prolactin Signaling
.54
Thrombopoietin Pathway
.51
Growth Hormone Signaling
.49
ErbB2-ErbB3 Heterodimers
.49
IL-2 Pathway
.48
|
LPS Stimulated MAPK Signaling
.47
UVC-Induced MAPK Signaling
.44
TREM1 Pathway
.43
PACAP Signaling
.37
HMGB1 Pathway
.36
PI3K Signaling in B-Lymphocyte
.35
IL-4 Pathway
.34
|
4 | Regulation of lipid metabolism Insulin signaling-generic cascades |
Regulation of lipid metabolism Insulin signaling-generic cascades
.59
Translation Insulin regulation of translation
.59
Transcription Receptor-mediated HIF regulation
.51
Translation Regulation of EIF2 activity
.47
Translation Regulation of EIF4F activity
.44
Development CNTF receptor signaling
.43
|
Cell adhesion PLAU signaling
.35
Development Growth hormone signaling via PI3K/AKT and MAPK cascades
.34
|
5 | Common Cytokine Receptor Gamma-Chain Family Signaling Pathways |
Immune response IL-9 signaling pathway
.42
Development Thrombopoietin-regulated cell processes
.38
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000165 | MAPK cascade | TAS | -- |
GO:0000186 | activation of MAPKK activity | TAS | -- |
GO:0000187 | activation of MAPK activity | TAS | -- |
GO:0006468 | protein phosphorylation | TAS | 11404397 |
GO:0006915 | apoptotic process | TAS,IEA | -- |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Arsenic trioxide | Approved, Investigational | Pharma | Target, inducer, inhibitor | 131 | ||
Isoproterenol | Approved, Investigational | Pharma | Agonist, Full agonist, Target, inducer | 31 | ||
Aspirin | Approved, Vet_approved | Pharma | Channel blocker, Target | 1512 | ||
Minocycline | Approved, Investigational | Pharma | Target, inhibitor | 229 | ||
Turpentine | Approved, Experimental | Pharma | Target | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
ADP |
|
Agonist, Full agonist, Partial agonist, Gating inhibitor, Antagonist | 58-64-0 |
|
Compound | Action | Cas Number |
---|---|---|
Eicosapentaenoic Acid | Endogenous polyunsaturated fatty acid; stimulates ERK1/2 phosphorylation | 10417-94-4 |
FR 180204 | Selective ERK inhibitor | 865362-74-9 |
Pluripotin | Dual ERK1/RasGAP inhibitor. Maintains ESC self-renewal | 839707-37-8 |
XMD 8-92 | ERK5/BMK1 inhibitor; also BRD4 inhibitor | 1234480-50-2 |
Compound | Action | Cas Number |
---|---|---|
DEL-22379 | inhibitor of the dimerization of ERK | 181223-80-3 |
FR 180204 | ERK inhibitor | 865362-74-9 |
Piperine | MAPK inhibitor | 94-62-2 |
SCH772984 | ERK1 and ERK2 inhibitor | 942183-80-4 |
TIC10 | Potent Akt/ERK inhibitor | 41276-02-2 |
VRT752271 | ERK1/ERK2 inhibitor | 869886-67-9 |
VX-11e | ERK inhibitor | 896720-20-0 |